Safety and vasopressor effect of rosuvastatin in septic patients
Conclusions Rosuvastatin 20mg/day in septic patients increased number ABPSPD, decreased time to initial ABPSPD, norepinephrine dose and duration, with no significant elevation in transaminases or CPK.
Source: Egyptian Journal of Anaesthesia - Category: Anesthesiology Source Type: research
More News: Anesthesia | Anesthesiology | Cholesterol | Crestor | Intensive Care | Perfusion | Rosuvastatin | Statin Therapy | Study